THE 2025 FFRD CALL FOR PROJECTS IS CLOSED
The FFRD wants to thank all the applicants for their interest 
More than 40 Francophone candidates registered on our submission platform (WIIN).
More than 30 of them submitted their applications before the May 12 deadline!
UPCOMING DEADLINES
Preselection of 5 to 7 candidates on Thursday 10th July by the Scientific Council,
Face-to-face interviews on Tuesday 9th September 2025 in Paris (Saint-Lazare).
NEXT STEP: search for international experts, out from the FFRD, to review the files.
Promoting and supporting research on diabetes, the pathophysiology of its various forms, its prevention and management, its comorbidities and its complications… for the advancement of diabetes research so that the burden of the desease can reduce. 
Review of the FFRD symposium on the Beta Cell “live”!
Experience the FFRD symposium on “Beta Cell” as if you were there! This event took place during last year’s SFD congress in Toulouse, highlighting fundamental…
Compilation and ranking of opinions from consulted experts
for submission to the Scientific Council, including the rapporteurs
Terms definition for the next press briefing
Communication and visibility update for FFRD
Financial update (donors and recipients)
The Francophone Foundation for Diabetes Research (FFRD) serves as the “armed wing” of the Francophone Diabetes Society (SFD) with the aim of promoting excellence in diabetes research, a common disease whose prevalence continues to rise. High-level and large-scale research is truly essential to get further insight into the mechanisms involved in the development of diabetes and its complications, as well as to improve their treatment and prevention.
The FFRD supports clinical, basic, and translational research.
The supported basic research projects address major themes of type 1 and type 2 diabetes
covering subjects such as pancreatic beta cells, insulin resistance, and intestinal microbiota.
The clinical research projects, on the other hand, address the themes of type 1 and type 2 diabetes, as well as gestational diabetes
and often involve large multicenter cohort studies.
Since 2013, the Foundation has been:
